Astrazeneca Plc $AZN Shares Purchased by MGO One Seven LLC

MGO One Seven LLC boosted its stake in Astrazeneca Plc (NYSE:AZN) by 10.0% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 51,051 shares of the company’s stock after acquiring an additional 4,627 shares during the period. MGO One Seven LLC’s holdings in Astrazeneca were worth $8,959,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Bank of Montreal Can increased its position in Astrazeneca by 344.6% during the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after buying an additional 2,695,793 shares in the last quarter. Holocene Advisors LP lifted its position in shares of Astrazeneca by 41.8% in the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after acquiring an additional 1,807,565 shares in the last quarter. Raymond James Financial Inc. boosted its stake in shares of Astrazeneca by 64.8% during the second quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock valued at $264,373,000 after acquiring an additional 1,487,662 shares during the last quarter. Bank of America Corp DE increased its position in Astrazeneca by 4.7% during the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after purchasing an additional 1,461,786 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Astrazeneca by 750.5% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,628,771 shares of the company’s stock worth $149,147,000 after purchasing an additional 1,437,253 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on AZN shares. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a report on Thursday, April 30th. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a report on Monday. UBS Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Finally, Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Stock Down 1.2%

Shares of NYSE:AZN opened at $182.67 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The firm has a market cap of $283.30 billion, a price-to-earnings ratio of 27.43, a PEG ratio of 1.52 and a beta of 0.26. The stock’s 50-day moving average price is $194.66 and its two-hundred day moving average price is $180.88. Astrazeneca Plc has a 12-month low of $132.32 and a 12-month high of $212.71.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The business had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. On average, research analysts forecast that Astrazeneca Plc will post 10.26 EPS for the current year.

Astrazeneca Dividend Announcement

The business also recently declared a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were paid a dividend of $1.595 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s dividend payout ratio (DPR) is currently 65.17%.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.